On April 29, the shares of Sihuan Bio (000518) rose sharply, and as of 14:37, Sihuan Bio was up 5%.Pokerpowerrankings.14%, at 2.25 yuan per share, with a transaction of 45.34 million yuan and a turnover rate of 2.01%.
News interpretation
On April 29, Zhang Chengzhong, member of the standing Committee of the Hebei Provincial CPC Committee and executive vice governor, was held at the State Development Office.PokerpowerrankingsHebei Province has promoted the "acceleration" of electronic information, biomedicine and other emerging industries in recent years, according to a series of news conferences on "promoting high-quality development". In 2023, the revenue of the biomedical industry exceeded 100 billion yuan, the revenue of the electronic information industry exceeded 300 billion yuan, and the investment in the province's high-tech industry increased by 24.7%. Hebei is implementing the development action of strategic emerging industrial clusters, focusing on supporting nine industrial clusters, including biomedicine, electronic information, and new energy vehicles, and cultivating eight industrial clusters, including new materials, safety emergency equipment, and modern Chinese medicine. We will promote the development of strategic emerging industries from agglomeration to cluster development.
Recently, Heilongjiang Lianshun Biotechnology Co., Ltd. passed the examination and formally joined Jiangmen Biopharmaceutical Industry Technology Innovation Alliance. It will exchange technology, share resources with alliance members, and enable the construction of industrial innovation ecosystem.
On April 28, the Beijing Municipal Bureau of economy and Information Technology, the Tianjin Bureau of Industry and Information Technology, and the Department of Industry and Information Technology of Hebei Province signed the "Cooperation Framework Agreement on the Co-Construction of Beijing-Tianjin-Hebei Cangzhou Biopharmaceutical Industrial Park" in Cangzhou Lingang Economic and technological Development Zone. We will carry out comprehensive cooperation on jointly promoting the collaborative innovation and co-construction of the Beijing-Tianjin-Hebei Biopharmaceutical Industry Park, and jointly build a biomedical industry cluster around the Bohai Sea.
On April 26, Henan Zhengzhou airport "financial living room" launching ceremony and biomedical health industry and financial docking meeting was held in Zhengzhou airport. Ten enterprises from Beijing, Shanghai, Jiangsu, Henan and other places took to the stage in turn to promote their development advantages, core competitiveness, listing plans and industry development.
The national first group standard of "Guide to Science and Technology Innovation Finance supporting Biomedical High-value Patent Transformation Service" was officially released in Shanghai on April 19. The group standard combines science and technology finance with the transformation of high-value biomedical patents for the first time, and proposes "team of scientists" + "long period" according to the characteristics of "frontier scientists". As a combination of risk coverage and risk slow release, the benefits of "predictable, stable and sustained high-value patents".
Mechanism analysis
China Merchants Securities Co., Ltd. said that 2024Q1 SW biomedical industry public offering funds accounted for 11.36% of heavy holdings, down 297 BP compared with 2023Q4, while non-pharmaceutical funds accounted for 6.43%, down 710bp compared with 2023Q4. 2024Q1 pharmaceutical industry overmatch rate of 6.60%, compared with the 2023Q4 month-on-month increase 21bp. From the SW secondary industry plate point of view, in addition to the proportion of pharmaceutical commercial positions slightly increased, other segments of the plate have varying degrees of decline.
Capital trend
As of press time, the main net inflow of Sihuan organisms was 8.41 million yuan, of which super-large single inflow was 3.7 million yuan and large single inflow was 4.7 million yuan. Data show that today's net inflow of the stock has increased by 7.22 million yuan compared with the average net inflow of nearly 5 days.
Main business and performance
Sihuan Biology Co., Ltd. is mainly engaged in pharmaceutical product research and development, production, sales and greening garden engineering business.
According to the latest financial report, in the three quarters of this year, Sihuan Bio realized operating income of 180 million yuan, down 8.49% from the same period last year, and its net profit was-43.3175 million yuan, down 22.52% from the same period last year.
(the above content is Portfolio based on public information, intelligently generated by programs or algorithms, only as a reference for users to view the market, not as investment advice or transaction basis. The stock market is risky, please make a careful decision. )